Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy

Paul J. Pockros, Mitchell L. Shiffman, Eugene R Schiff, Mark S. Sulkowski, Zobair Younossi, Douglas T. Dieterich, Teresa L. Wright, Samir H. Mody, K. Linda Tang, Betty L. Goon, Peter J. Bowers, Gerhard Leitz, Nezam H. Afdhal

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Anemia and decreased health-related quality of life (HRQL) are common in patients receiving combination therapy of interferon alfa (IFN) and ribavirin (RBV) for chronic hepatitis C virus (HCV) infection. In a randomized, prospective study evaluating the effectiveness of epoetin alfa in maintaining RBV dose, alleviating anemia, and improving HRQL in anemic (Hb ≤ 12 g/dL) HCV-infected patients receiving combination therapy, patients receiving epoetin alfa had significant improvements in HRQL compared with placebo. In this study, 185 patients were randomized to 40,000 units of epoetin alfa subcutaneously weekly or placebo for an 8-week double-blind phase (DBP), followed by an 8-week open-label phase during which all patients received epoetin alfa. To further assess the impact of epoetin alfa on HRQL, post hoc analyses were conducted in the same patient population to compare the HRQL of these patients at randomization with norms of other populations, and to determine the critical relationship between hemoglobin (Hb) levels and HRQL. Mean HRQL scores of anemic HCV-infected patients receiving combination therapy at randomization were significantly lower than those of both the general population and patients who had other chronic conditions. Patients receiving epoetin alfa who had the greatest Hb increases from randomization to the end of the DBP also had the largest improvements in HRQL. Hb improvement was an independent predictor of HRQL improvement in these patients. In conclusion, epoetin alfa provided clinically significant HRQL improvement in HCV-infected patients receiving IFN/RBV therapy.

Original languageEnglish
Pages (from-to)1450-1458
Number of pages9
JournalHepatology
Volume40
Issue number6
DOIs
StatePublished - Dec 1 2004

Fingerprint

Epoetin Alfa
Hepacivirus
Quality of Life
Ribavirin
Hemoglobins
Therapeutics
Random Allocation
Quality Improvement
Interferon-alpha
Anemia
Placebos

ASJC Scopus subject areas

  • Hepatology

Cite this

Pockros, P. J., Shiffman, M. L., Schiff, E. R., Sulkowski, M. S., Younossi, Z., Dieterich, D. T., ... Afdhal, N. H. (2004). Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology, 40(6), 1450-1458. https://doi.org/10.1002/hep.20482

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. / Pockros, Paul J.; Shiffman, Mitchell L.; Schiff, Eugene R; Sulkowski, Mark S.; Younossi, Zobair; Dieterich, Douglas T.; Wright, Teresa L.; Mody, Samir H.; Tang, K. Linda; Goon, Betty L.; Bowers, Peter J.; Leitz, Gerhard; Afdhal, Nezam H.

In: Hepatology, Vol. 40, No. 6, 01.12.2004, p. 1450-1458.

Research output: Contribution to journalArticle

Pockros, PJ, Shiffman, ML, Schiff, ER, Sulkowski, MS, Younossi, Z, Dieterich, DT, Wright, TL, Mody, SH, Tang, KL, Goon, BL, Bowers, PJ, Leitz, G & Afdhal, NH 2004, 'Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy', Hepatology, vol. 40, no. 6, pp. 1450-1458. https://doi.org/10.1002/hep.20482
Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology. 2004 Dec 1;40(6):1450-1458. https://doi.org/10.1002/hep.20482
Pockros, Paul J. ; Shiffman, Mitchell L. ; Schiff, Eugene R ; Sulkowski, Mark S. ; Younossi, Zobair ; Dieterich, Douglas T. ; Wright, Teresa L. ; Mody, Samir H. ; Tang, K. Linda ; Goon, Betty L. ; Bowers, Peter J. ; Leitz, Gerhard ; Afdhal, Nezam H. / Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. In: Hepatology. 2004 ; Vol. 40, No. 6. pp. 1450-1458.
@article{023742db53bc4e0f9933f37abd7152cd,
title = "Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy",
abstract = "Anemia and decreased health-related quality of life (HRQL) are common in patients receiving combination therapy of interferon alfa (IFN) and ribavirin (RBV) for chronic hepatitis C virus (HCV) infection. In a randomized, prospective study evaluating the effectiveness of epoetin alfa in maintaining RBV dose, alleviating anemia, and improving HRQL in anemic (Hb ≤ 12 g/dL) HCV-infected patients receiving combination therapy, patients receiving epoetin alfa had significant improvements in HRQL compared with placebo. In this study, 185 patients were randomized to 40,000 units of epoetin alfa subcutaneously weekly or placebo for an 8-week double-blind phase (DBP), followed by an 8-week open-label phase during which all patients received epoetin alfa. To further assess the impact of epoetin alfa on HRQL, post hoc analyses were conducted in the same patient population to compare the HRQL of these patients at randomization with norms of other populations, and to determine the critical relationship between hemoglobin (Hb) levels and HRQL. Mean HRQL scores of anemic HCV-infected patients receiving combination therapy at randomization were significantly lower than those of both the general population and patients who had other chronic conditions. Patients receiving epoetin alfa who had the greatest Hb increases from randomization to the end of the DBP also had the largest improvements in HRQL. Hb improvement was an independent predictor of HRQL improvement in these patients. In conclusion, epoetin alfa provided clinically significant HRQL improvement in HCV-infected patients receiving IFN/RBV therapy.",
author = "Pockros, {Paul J.} and Shiffman, {Mitchell L.} and Schiff, {Eugene R} and Sulkowski, {Mark S.} and Zobair Younossi and Dieterich, {Douglas T.} and Wright, {Teresa L.} and Mody, {Samir H.} and Tang, {K. Linda} and Goon, {Betty L.} and Bowers, {Peter J.} and Gerhard Leitz and Afdhal, {Nezam H.}",
year = "2004",
month = "12",
day = "1",
doi = "10.1002/hep.20482",
language = "English",
volume = "40",
pages = "1450--1458",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy

AU - Pockros, Paul J.

AU - Shiffman, Mitchell L.

AU - Schiff, Eugene R

AU - Sulkowski, Mark S.

AU - Younossi, Zobair

AU - Dieterich, Douglas T.

AU - Wright, Teresa L.

AU - Mody, Samir H.

AU - Tang, K. Linda

AU - Goon, Betty L.

AU - Bowers, Peter J.

AU - Leitz, Gerhard

AU - Afdhal, Nezam H.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Anemia and decreased health-related quality of life (HRQL) are common in patients receiving combination therapy of interferon alfa (IFN) and ribavirin (RBV) for chronic hepatitis C virus (HCV) infection. In a randomized, prospective study evaluating the effectiveness of epoetin alfa in maintaining RBV dose, alleviating anemia, and improving HRQL in anemic (Hb ≤ 12 g/dL) HCV-infected patients receiving combination therapy, patients receiving epoetin alfa had significant improvements in HRQL compared with placebo. In this study, 185 patients were randomized to 40,000 units of epoetin alfa subcutaneously weekly or placebo for an 8-week double-blind phase (DBP), followed by an 8-week open-label phase during which all patients received epoetin alfa. To further assess the impact of epoetin alfa on HRQL, post hoc analyses were conducted in the same patient population to compare the HRQL of these patients at randomization with norms of other populations, and to determine the critical relationship between hemoglobin (Hb) levels and HRQL. Mean HRQL scores of anemic HCV-infected patients receiving combination therapy at randomization were significantly lower than those of both the general population and patients who had other chronic conditions. Patients receiving epoetin alfa who had the greatest Hb increases from randomization to the end of the DBP also had the largest improvements in HRQL. Hb improvement was an independent predictor of HRQL improvement in these patients. In conclusion, epoetin alfa provided clinically significant HRQL improvement in HCV-infected patients receiving IFN/RBV therapy.

AB - Anemia and decreased health-related quality of life (HRQL) are common in patients receiving combination therapy of interferon alfa (IFN) and ribavirin (RBV) for chronic hepatitis C virus (HCV) infection. In a randomized, prospective study evaluating the effectiveness of epoetin alfa in maintaining RBV dose, alleviating anemia, and improving HRQL in anemic (Hb ≤ 12 g/dL) HCV-infected patients receiving combination therapy, patients receiving epoetin alfa had significant improvements in HRQL compared with placebo. In this study, 185 patients were randomized to 40,000 units of epoetin alfa subcutaneously weekly or placebo for an 8-week double-blind phase (DBP), followed by an 8-week open-label phase during which all patients received epoetin alfa. To further assess the impact of epoetin alfa on HRQL, post hoc analyses were conducted in the same patient population to compare the HRQL of these patients at randomization with norms of other populations, and to determine the critical relationship between hemoglobin (Hb) levels and HRQL. Mean HRQL scores of anemic HCV-infected patients receiving combination therapy at randomization were significantly lower than those of both the general population and patients who had other chronic conditions. Patients receiving epoetin alfa who had the greatest Hb increases from randomization to the end of the DBP also had the largest improvements in HRQL. Hb improvement was an independent predictor of HRQL improvement in these patients. In conclusion, epoetin alfa provided clinically significant HRQL improvement in HCV-infected patients receiving IFN/RBV therapy.

UR - http://www.scopus.com/inward/record.url?scp=10644237092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10644237092&partnerID=8YFLogxK

U2 - 10.1002/hep.20482

DO - 10.1002/hep.20482

M3 - Article

C2 - 15565613

AN - SCOPUS:10644237092

VL - 40

SP - 1450

EP - 1458

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 6

ER -